Melatonin in Endometriosis: Mechanistic Understanding and Clinical Insight

Yiran Li 1,†, Sze-Wan Hung 1,†, Ruizhe Zhang 2, Gene Chi-Wai Man 1,*, Tao Zhang 1, Jacqueline Pui-Wah Chung 1, Lanlan Fang 2,* and Chi-Chiu Wang 1,3,4,5,*

1 Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong 999077, China
2 Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
3 Laboratory of Reproduction and Development, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong 999077, China
4 School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong 999077, China
5 Chinese University of Hong Kong-Sichuan University Joint Laboratory in Reproductive Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China
* Correspondence: fanglly@163.com (L.F.); ccwang@cuhk.edu.hk (C.-C.W.); Tel.: +86-371-6691-3635 (L.F.); +852-3505-4267 (C.-C.W.)
† These authors contributed equally to this work.

Abstract: Endometriosis is defined as the development of endometrial glands and stroma outside the uterine cavity. Pathophysiology of this disease includes abnormal hormone profiles, cell survival, migration, invasion, angiogenesis, oxidative stress, immunology, and inflammation. Melatonin is a neuroendocrine hormone that is synthesized and released primarily at night from the mammalian pineal gland. Increasing evidence has revealed that melatonin can be synthesized and secreted from multiple extra-pineal tissues where it regulates immune response, inflammation, and angiogenesis locally. Melatonin receptors are expressed in the uterus, and the therapeutic effects of melatonin on endometriosis and other reproductive disorders have been reported. In this review, key information related to the metabolism of melatonin and its biological effects is summarized. Furthermore, the latest in vitro and in vivo findings are highlighted to evaluate the pleiotropic functions of melatonin, as well as to summarize its physiological and pathological effects and treatment potential in endometriosis. Moreover, the pharmacological and therapeutic benefits derived from the administration of exogenous melatonin on reproductive system-related disease are discussed to support the potential of melatonin supplements toward the development of endometriosis. More clinical trials are needed to confirm its therapeutic effects and safety.

Keywords: melatonin; endometriosis; anti-inflammatory; inflammatory disease; clinical trials; in vitro studies; animal studies

1. Introduction

Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone synthesized and released at night from the pineal gland. This hormone has been shown to regulate the circadian rhythm of the body, pubertal development, and seasonal adaptation [1,2]. It has also been reported to act directly on the hypothalamic–pituitary–gonad (HPG) axis to regulate reproduction [3,4]. For many years, melatonin has only been considered as a hormone to be secreted exclusively by the pineal gland. In recent years, it has been shown that this hormone can be produced by many extra-pineal tissues to exert its biological functions locally [5]. As a pleiotropic molecule, melatonin can interact with female reproductive organs, including the ovaries, uterus, mammary glands, and placenta, to regulate many physiological and pathological events [6,7]. Several studies have shown the capabilities of melatonin to improve fertilization in sub-fertile patients [8]. The beneficial effects of melatonin in reproduction can be attributed to its well-characterized antioxidative effect and...
other biological functions, such as the regulation of steroid hormone production, anti-cell proliferation, pro-apoptosis, anti-cell adhesion, anti-invasion, anti-epithelial-mesenchymal transition (EMT), anti-angiogenic activity, and regulation of immune modulation as well as neurotrophic effects [9].

Endometriosis is a chronic disease that can be defined as the development of endometrial glands and stroma on the uterine cavity [10]. It is estimated that endometriosis affects 5 to 10% of women between 25 and 35 years old [10]. Endometriosis is an estrogen-dependent inflammatory disease that affects women at reproductive stage and leads to sterility. Typical symptoms of endometriosis include chronic pelvic pain, dysmenorrhea, and dyspareunia.

The pathogenesis of endometriosis is not yet fully understood. Despite several proposed theories on the etiology of endometriosis, none of these models can fully explain the pathogenesis of this disease. Regardless of this, it is commonly theorized to arise from the endometrial fragments escaping into the peritoneal cavity through the process of retrograde menstruation. Meanwhile, abnormal endocrine, immunology, pro-inflammatory, and proangiogenic pathways may contribute to the development of endometriosis [11,12]. Additionally, many abnormal cellular functions, including cell proliferation and migration/invasion, have been shown to induce the process [13]. Misinterpretation of endometriosis-induced pain, such as menstruation-associated abdominal cramps, can often delay the diagnosis of endometriosis by up to 8 to 10 years [14]. Treatment of endometriosis is mainly used to alleviate the symptoms and increase fertility rates [15]. Hormonal compounds and symptomatic treatments are the major medications to treat endometriosis, including non-steroidal anti-inflammatory drugs, gonadotropin-releasing hormone agonists, progestins, and oral contraceptive pills [16]. As these medications bring side effects by creating a hypoestrogenic state to suppress ovarian functions, women of childbearing age should instead only use pain relief [15]. As a consequence, it is highly crucial to develop potential new treatments that do not interfere with the reproductive functions in women suffering from endometriosis. As the occurrence of endometriosis cannot be explained by any single pathophysiological event, therapeutic drugs should be multi-targeted to resolve the disease complexity [17]. Regarding this, melatonin could be a potential candidate as an ideal medication for the treatment of endometriosis. With melatonin demonstrating a potential therapeutic effect against endometriosis in an early clinical study, its therapeutic targets and molecular mechanism are worth exploring further [18].

Considering that several melatonin-involved pathways might be relevant to the pathophysiology of endometriosis, there is currently no review dedicated to melatonin as a potential treatment of endometriosis. Hence, a more comprehensive evaluation of the effects of melatonin in treating endometriosis is worth deliberating. This review aims to explain the biology and molecular mechanism of melatonin and emphasizes its potential clinical applications for treating endometriosis.

2. The Biology of Melatonin

2.1. Synthesis

The classic melatonin biosynthetic pathway includes five enzymatic steps in animals. In the first step, tryptophan is hydroxylated to 5-hydroxytryptophan by tryptophan-5-hydroxylase (TPH); consequently, it is decarboxylated to serotonin (5-hydroxytryptamine) by the aromatic amino acid decarboxylase (AADC). In the two final steps, it is proposed that serotonin is acetylated by aralkylamine N-acetyltransferase (AANAT) to N-acetylserotonin. Ultimately, this works as an intermediate to form N-acetyl-5-methoxytryptamine, also known as melatonin, exclusively in the pineal gland in animals [19]. After synthesis from the pineal gland, melatonin passes to the hypothalamic suprachiasmatic nuclei (SCN) via the polysynaptic pathway. Additionally, in recent year, multiple studies have also shown that melatonin could be produced in several extra-pineal organs, including the retina, skin, gastrointestinal tract, and bone marrow, and act locally through autocrine and/or paracrine
manners [20], while for the female reproductive system, melatonin was found to be secreted by the uterus, ovaries, and placenta [21].

2.2. Metabolism

The circadian melatonin cycle is at maximum at night and minima during the day. The plasma half-life of melatonin is relatively short, around 20 to 50 minutes [22]. Melatonin is highly soluble in both water and lipids. Therefore, it easily diffuses through the cell membrane and the blood–brain barrier [23]. In humans, melatonin is mainly metabolized to 6-hydroxymelatonin (6-HMEL) that serves as a surrogate of circulatory melatonin levels by the liver enzyme cytochrome P450 1A2 (CYP1A2), which is then subsequently conjugated with sulfate and is excreted in the urine [24]. For exogenous melatonin, the peak plasma/serum concentration (Tmax) is achieved at approximately 50 min after oral administration of melatonin in an immediate-release dosage form. In accordance, the elimination half-life (T1/2) of melatonin for both oral and intravenous administration was 45 min [25].

2.3. Receptors

In humans, there have been two main isoforms of the membrane-bound melatonin receptors (MTs), namely MT1 and MT2, identified in the plasma and peripheral tissues [22]. Both of them belong to the G protein-coupled receptors (GPCRs) family. The key biological effects of melatonin are exerted by activating through MT1 and MT2 in humans [22]. After the two receptors couple to Gα/i/o proteins, intracellular levels of the second messenger cyclic adenosine monophosphate (cAMP) are consequently decreased, which is the most common signaling pathway activated by melatonin [26], such that MT1 and MT2 receptors have a high density of expressions in the neuroendocrine system, such as the hypothalamic SCN, pituitary pars tuberalis (PT), and gonadotroph cells [27,28]. These receptors are also expressed in several peripheral organs, including skin, vasculature, gastrointestinal tract, and kidney [29–32]. In the reproductive system, melatonin receptors can be detected in the placenta, uterus, and endometrium [33–35]. These biological effects are mediated by the interaction of melatonin with MT1/MT2 for activating other molecular pathways. For instance, melatonin may act as a ligand for the family of orphan retinoid-linked nuclear receptors (RZR/ROR), including RZRα, RORα, RORα2, and RZRβ [36].

2.4. Biological Effects

Besides being known to regulate the circadian rhythm, new evidence indicates that melatonin can act as a regulator in the endocrine, cardiovascular, immune, and neural systems [37–40]. Melatonin exerts these effects by working as a potent antioxidant that can directly scavenge free radicals, oxygen-centered radicals, and other toxic hydroxyl radicals [41,42]. Owing to its potent antioxidant properties, melatonin can promote apoptosis with anti-inflammatory and anti-angiogenesis capabilities toward various carcinomas [43–45]. Likewise, melatonin has been shown to play a key role in reproduction and women’s health. For instance, studies have shown a significant and positive impact on the maturation of the oocyte and subsequent embryonic development [46]. In addition, patients who were given melatonin during in vitro fertilization and embryo transfer (IVF-ET) are likely to increase the success rate of the IVF-ET treatment [47]. Regarding endometriosis, women who worked during night shifts were reported to have decreased pineal gland melatonin production and an increased risk of endometriosis, hinting at a possible correlation between melatonin and endometriosis [48,49].

3. Potential Therapeutic Mechanisms of Melatonin in Endometriosis

In studies using a model of endometriosis, melatonin was shown to prevent and treat endometriosis by reducing the size and weight of the endometriotic lesions [50–52], while in women with endometriosis, MT2 protein expression was significantly decreased in peritoneal lesions compared to eutopic endometrium [53]. A randomized phase II double-
blinded, placebo-controlled clinical trial demonstrated that melatonin could alleviate pain in endometriosis [18]. Details are summarized below.

Current evidence suggests that melatonin supplements are safe for short-term use [54]. Even when taken at extreme doses, only mild adverse effects such as dizziness, sleepiness, nausea, and headache have been reported [55,56]. No studies have indicated that exogenous melatonin would induce any serious adverse effects. In addition, clinical studies have proven the safety profile of exogenous melatonin to be used as a supplement, particularly in obstetrics and reproductive-related conditions, such as for fertility [57]. These studies showed the potential of melatonin as a therapeutic drug for endometriosis without any negative effect on the reproductive system. Similarly, randomized clinical studies indicate that long-term melatonin treatment causes only mild adverse effects comparable to a placebo. Long-term safety of melatonin in children and adolescents, however, requires further investigation. The schematic diagram of the potential therapeutic effects of melatonin on endometriosis is shown in Figure 1. The studies related to the determined effects of melatonin on endometriosis are summarized in Table 1. In addition, the effects of exogenous melatonin in the rat model of endometriosis are compared in Figure 2.

**Figure 1.** Therapeutic targets of melatonin toward inhibiting the development and progression of endometriosis. The effect of melatonin with respect to various molecular targets involved in the processes of endometriosis, including adhesion, invasion, EMT, oxidative stress, angiogenesis, and chronic pelvic pain. Abbreviations: MMP, Matrix metalloproteinase; TIMP, Tissue inhibitors of metalloprotease; EMT, Epithelial–mesenchymal transition; MDA, Malondialdehyde; COX-2, Cyclooxygenase 2; SOD, Superoxide dismutase; CAT, Catalase; VEGF, Vascular endothelial growth factor; BDNF, Brain-derived neurotrophic factor.
Table 1. Experimental studies of melatonin for endometriosis.

| Studies     | Study Type | Study Sample Specie | Models/Methods                                      | Dose         | Route   | Duration     | Results                                                                 | Mechanism                                                                 |
|-------------|------------|---------------------|-----------------------------------------------------|--------------|---------|--------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Guney 2008  | Animal in vivo | rats                | Endometrium fragments sutured to the abdominal wall | 10 mg/kg daily | ip      | 4 weeks      | Decreased lesion sizes and weight                                       | Increased SOD, CAT, Decreased MDA, COX-2                                   |
| Paul 2008   | Animal in vivo | mice                | Intraperitoneal transplantation                      | 48 mg/kg daily | ip      | 10 or 20 days| /                                                                         | Increased TIMP-1, Decreased MMP-9                                         |
| Paul 2010   | Animal in vivo | mice                | Intraperitoneal transplantation                      | 48 mg/kg daily | ip      | 10 or 20 days| /                                                                         | Increased TIMP-3, Decreased MMP-3                                         |
| Yildirim 2010 | Animal in vivo | rats                | Endometrium fragments sutured to the abdominal wall | 10 mg/kg daily | ip      | 2 weeks      | Decreased lesion sizes, Decreased histopathologic scores                | Increased SOD, CAT                                                        |
| Koc 2010    | Animal in vivo | rats                | Endometrium fragments sutured to the abdominal wall | 10 mg/kg daily | ip      | 4 weeks      | Decreased histopathologic score                                         | Increased SOD, CAT, Decreased MDA                                        |
| Kocadal 2013 | Animal in vivo | rats                | Intraperitoneal transplantation                      | 20 mg/kg daily | im and ip | 2 weeks      | Decreased lesion sizes, Decreased histopathologic scores               | /                                                                         |
| Yilmaz 2015 | Animal in vivo | rats                | Endometrium fragments sutured to the abdominal wall | 10 mg/kg daily | ip      | 4 weeks      | Decreased lesion weight, Decreased histopathologic scores              | Increased SOD, MDA, TIMP-2, Decreased VEGF, MMP-9                        |
| Cetinkaya 2015 | Animal in vivo | rats                | Endometrium fragments sutured to the abdominal wall | 10 or 20 mg/kg daily | im and ip | 2 weeks      | Decreased lesion sizes in both treatment groups without significant difference | /                                                                         |
| Shasha 2018  | Cell in vitro | human               | Endometriotic eutopic epithelial cell culture        | 1 mM         | culture medium | 72 h        | /                                                                         | Increased Numb, E-cadherin, Decreased migration, invasion and Notch1, Vimentin, Slug, Snail |

ip, Intraperitoneal injection; im, Intramuscular injection; SOD, Superoxide dismutase; CAT, Catalase; MDA, Malondialdehyde; COX-2, Cyclooxygenase 2; TIMP, Tissue inhibitors of metalloprotease; MMP, Matrix metalloproteinase; VEGF, Vascular endothelial growth factor.
**Figure 2.** Forest plots of effectiveness of melatonin treatment compared with control in endometriosis. Forest plot of included studies comparing the effect of exogenous melatonin (10 mg/kg) in a rat model of endometriosis. (A) Lesion size at 2 weeks [50,51,61]. (B) Lesion size at 4 weeks [50,58,61,62]. (C) Histopathological score after 2 weeks [50,51,61]. (D) Histopathological score after 4 weeks [50,58,61,62]. (E) Level of superoxide dismutase (SOD) after 2 weeks [50,58,62].
3.1. Anti-Oxidation

As endometriosis patients are prominently known to have an upregulated level of reactive oxygen species (ROS), the insufficient antioxidants would prompt a deleterious effect from the imbalance between ROS and antioxidants [65]. The elevated ROS in endometriosis can lead to cellular damage and other undesirable side effects, including a systemic inflammatory reaction and endometriosis-related infertility [66]. With melatonin being a free-radical scavenger and a potent stimulator of antioxidant enzymes, it has been proposed as a potential therapeutic agent to prevent the onset of endometriosis by enhancing the antioxidant levels. Based on an animal study, melatonin was shown to downregulate cyclooxygenase 2 (COX-2) and malondialdehyde (MDA) protein levels and upregulate SOD and catalase (CAT) in the endometriotic lesions [58], while in another in vivo study, melatonin also demonstrated upregulating levels of antioxidants, such as SOD and CAT [52]. Likewise, activities of lipid peroxidation (LP) were induced, and antioxidants, including SOD and CAT, were reduced in an endometriosis rat model after undergoing pinealectomy [62]. Interestingly, these effects were effectively reversed by the introduction of exogenous melatonin [62]. Similarly, the MDA levels and histopathological scores of endometriosis were significantly reduced, with no alteration in SOD levels, in the human xenograft model of endometriosis when treated with melatonin for 4 weeks [67]. Another study also revealed similar results in demonstrating the capability of melatonin to upregulate SOD levels and decreased histopathological scores, but with a discrepancy in the increased MAD level [51].

In general, melatonin has been shown to elicit a tendency to prevent oxidative stress in organs requiring high oxygen consumption (e.g., the brain) and those colonized with certain microbes to create a hostile environment, such as in the gut and skin [68,69]. Besides these, the beneficial role of melatonin as a potent antioxidant has also been demonstrated in the human reproductive system. As melatonin can reduce oxidative stress in follicles, it functioned by preventing the free radicals generated from causing harm on the oocytes [47]. In addition, melatonin can improve the uterine microenvironment by promoting the expression of antioxidant enzymes, such as SOD and CAT [70]. Moreover, these findings clearly illustrate that melatonin can potentially act as an antioxidant to treat endometriosis through the upregulation of antioxidant enzymes and downregulation of pro-oxidant enzymes. The studies related to the determined effects of melatonin on endometriosis are summarized in Table 1.

3.2. Regulation of Steroid Hormone Production and Function

Endometriosis is a disease of hormone imbalance, particularly referred to as an estrogen-dependent and progesterone (P4)-resistance disorder [10]. In contrast to normal endometrium, endometriotic tissues have a higher capability to synthesize E2 locally, due to the high expression of two of the key enzymes for estrogen biosynthesis: aromatase (CYP19A1) and steroidogenic acute regulatory protein (StAR) [71]. As the accumulated E2 can induce cell proliferation and inflammation, this would further stimulate the advancement and progression of endometriosis by promoting lesion growth and undermining the endometrial sensitivity [12,72]. In normal endometrium, the mediators of estrogenic action can be through the two receptors estrogen receptor alpha (ERα) (ESR1) and estrogen receptor beta (ERβ) (ESR2) [73]. Their regulation in endometriosis remains uncertain, such that one study suggested that patients with endometriosis would have downregulation of ERα and upregulation of ERβ [74]. On the contrary, another study showed that ERα and ERβ expression levels were both increased in ectopic tissue in comparison with the normal and eutopic endometrium [74]. Although there were mixed results, both studies supported that the ESR2/ESR1 ratio was increased in the endometriotic lesions. The upregulated estrogen activities would therefore cause progesterone resistance [75]. In addition, patients with endometriosis were reported to be unable to manifest P4 to activate its receptor (PGR) or the transcription of its target gene [76]. As a consequence, PGR-B in mRNA and protein concentrations were significantly downregulated in both endometriotic lesions and
endometrium [77–79]. In this regard, current studies have unveiled the regulatory effects of melatonin on P4 and E2 that would take place in tissue-specific manners and through a series of ongoing mechanisms [80].

3.2.1. Estrogen

Significant research has confirmed the tendency of melatonin in suppressing E2 production. A study conducted on hamster ovary showed that melatonin inhibited E2 synthesis from the preovulatory follicle via the MAPK pathway following treatment with human chorionic gonadotropin (hCG), a hormone to induce the corpus luteum to secrete E2 [81]. Long-term melatonin treatment in rats has been shown to significantly reduce 17 beta-estradiol levels in plasma, ERα expression levels in the ovary, and ERβ levels in the uterine tissue [82]. In a clinical trial, daily administration of 300 mg of melatonin for 4 months resulted in a significant reduction in estradiol level [83]. In preclinical studies on hormone-dependent breast cancer, melatonin was found to lower serum E2 levels, ESR expressions, and tumor growth in mice models, as well as reduce cell viability through the estrogen response pathway in a human breast cancer cell line [84–86]. On the other hand, melatonin was noted to stimulate the production of E2 through the activation of the PKA-CREB signaling pathway in human granulosa cells [87,88]. Aromatase, which is encoded by CYP19A1, is the core enzyme to catalyze the androgen biosynthesis to form E2 [89]. In human MCF-7 breast cancer cells, aromatase expression was suppressed by the binding of melatonin to MT1 for inhibiting downstream functions, such as cell growth, via the cAMP pathway [90,91]. Likewise, melatonin also can reduce E2 biosynthesis and blocked the growth of human umbilical vein endothelial cells (HUVECs) and rat glioma cells via the suppression of the aromatase level [92,93]. Interestingly, melatonin had a stimulating effect on the aromatase expression level in human granulosa cells [88]. The underlying cause of differential effects of melatonin could be explained by CYP19A1 being driven by different promoters at the upstream of the first exons in various tissues, which ultimately leads to the respective outcomes in different tissues [94,95]. Pinealectomy in rats has been reported to increase E2 synthesis and interfere with LH and FSH releases to result in anovulation [96]. Treatment with melatonin inhibited the proliferation of endometrial epithelial cells in the presence of E2 at 48 h after exposure [53]. In a rat endometriosis model, treatment with melatonin resulted in greater regression of endometriosis foci and reduced recurrence rate when compared to those treated with an aromatase inhibitor, letrozole [52]. Moreover, these studies illustrated that melatonin would not only regulate the E2 response pathway but would contribute to suppressing the E2 biosynthesis via aromatase activity.

3.2.2. Progesterone

To date, there is a great deal of related evidence suggesting that melatonin may play a role in regulating P4 resistance. In human granulosa cells, multiple findings showed that melatonin increased the production of P4 [97,98]. On the contrary, a study conducted on patients with uterine cancer showed that melatonin inhibited the production of P4 in human granulosa cells [99]. Meanwhile, some studies showed that melatonin had no direct effect on the production of P4 in human granulosa cells [100,101]. P4 resistance was a consequence of PGR dysregulation, as well as due to the reduction of StAR, a key enzyme in regulating the synthesis of P4. Melatonin enhanced PGR expression in mouse cumulus cells and induced the expression of StAR in human granulosa and bovine theca cells via the activation of the PI3K/AKT signaling pathway [98,102]. A similar upregulation effect was also observed in mammalian Leydig cells [103]. Other contradictory findings suggested that melatonin reduced PGR expression in the MCF-7 human breast cancer cell line [104,105]. P4 is essential for the development of endometrial pinopodes and microvilli. With the levels of P4 being reduced after pinealectomy, it further contributes to the outcome of a reduced number of implantations, indicating the potential role of melatonin [106]. Nevertheless, further studies on the function of melatonin on P4 regulation would still be warranted on hormonal balance.
3.3. Anti-Proliferation and Pro-Apoptosis

The endometrium maintains complex controls on proliferation and apoptosis as part of repetitive menstrual cycles that prepare the endometrium for the window of implantation and pregnancy. However, the occurrence of endometriosis would disrupt the balance between cell proliferation and apoptosis [10]. Melatonin was shown to regulate several pathways associated with proliferation and apoptosis in normal and cancer cells [107]. These pathways mainly mediate through nuclear factor-kappaB (NF-κB), PI3K/Akt, and cyclin-dependent kinases (CDKs) to promote cell proliferation [108], such that the regulatory activity of melatonin can be demonstrated by its capability to inhibit NF-κB activation in human lung cancer cell lines and liver cancer cell lines [109,110]. Likewise, melatonin (or in combination with vitamin D3) was found to inhibit proliferation via the PI3K/Akt pathway in a human breast cancer cell line [111,112]. Additionally, melatonin was shown to inhibit the RNA expressions of cyclins and CDKs to suppress the progression of the G1-phase in dopaminergic neuroblastoma cells in rats [113]. In addition, melatonin can inhibit the RNA expression level of cyclin D1 in human breast cancer cells and the RNA and protein expression levels of cyclin D1, cyclin B1, CDK1, and CDK4 in osteosarcoma cells [114,115]. Although there is currently no literature documenting the capability to downregulate proliferation via the above-mentioned pathways in endometriosis, several studies have shown that melatonin significantly suppressed eutopic endometrial lesions in endometriosis mouse models [52,58,63]. Additionally, melatonin could also inhibit the cell proliferation induced by estrogen in human endometrial epithelial cells [53]. However, melatonin can facilitate apoptosis through the modulation of various apoptotic mediators including mitochondria, Bax, Bcl-2, endogenous ROS, and apoptosis receptors [116]. In a study using a xenograft of endometriosis, it showed that the treatment of melatonin can enhance apoptotic cells while reducing the expression of Bcl-2 via the upregulation of Bax expression and promoting caspase 9 activation [60]. Taken together, these studies can indicate the potential of melatonin to possibly restore the balance of the endometrium on proliferation and apoptosis disrupted by the occurrence of endometriosis.

3.4. Anti-Adhesion and Anti-Invasion

Ectopic endometriosis cells have an advanced potential to invade immunosurveillance and attach to the lymph nodes and the abdominal cavity [117]. Viable glandular and stromal endometrial cells attach to the abdominal cavity through interacting with cell surface receptors, including integrins and membrane adhesion molecules in the extracellular matrix (ECM), such as fibronectin and laminin [117,118]. The mRNA and protein levels of collagen I and fibronectin were found to be inhibited by melatonin in a hindlimb ischemia mouse model [119]. Matrix metalloproteinases (MMPs) are a large family that can remodel ECM and regulate adhesion and invasion of cells [120]. MMP proteins were highly expressed in endometriotic tissues when compared to normal endometrium [121–123]. As the tissue inhibitors of metalloproteases (TIMPs) are endogenous inhibitors of MMPs, a significant reduction in the protein expressions of TIMP-1 and TIMP-2 in endometriotic diseased tissue was reported [124–126]. In another study, it was shown that eutopic endometrium and ectopic lesions of women with endometriosis had lower levels of TIMP-3 mRNA expression, while the MMP-9 mRNA level was solely enhanced in ectopic lesions [121]. Other studies also showed that the expression levels of MMP2, MMP3, and MMP9 in ectopic endometrium and endometriosis cells were amplified [127,128]. In accordance, melatonin was found to regulate MMP gene expression and activity in many diseases, such that melatonin could protect against endometriosis by regulating TIMP-1/MMP9 and TIMP3/MMP3 in the peritoneal endometriosis mice model on degrading ECM and regressing the growth of the endometriotic lesion [59,60]. Similarly, melatonin was found to increase TIMP-2 expression levels in the endometriosis rat model [51]. On the other hand, melatonin was shown to downregulate MMP2 and MMP9 expression levels in the gastric mucosa of rats, human gastric cancer cell lines, and human breast cancer cell lines [129–131]. It was also found to reduce the concentration of MMP9 in rat retina, human ovarian cells,
and breast cancer cells [132–134]. The downregulation in mRNA and protein levels of MMP2 and MMP9 can induce high glucose and IL-1β levels in human retinal endothelial cells and retinal pigment epithelial cells [135]. In addition, mice that were kept under different light conditions showed a dose-dependence effect of melatonin to inhibit the adhesion of the integrin-mediated granulocyte to intercellular adhesion molecule-coated plates via melatonin receptors [136]. Taken together, the pleiotropic role of melatonin would contribute to the effect of downregulation toward adhesion and invasion.

3.5. Anti-Epithelial–Mesenchymal Transition (Anti-EMT)

As EMT is defined as the process whereby epithelial cells are transformed into mesenchymal cells, it is an essential process to regulate endometriosis progression and metastasis [137]. To undergo the process of EMT, cells are required in the cycle of migration, invasion, and proliferation. In addition, signaling pathways, such as NF-κB, Wnt, Notch, and other crucial factors (e.g., Snail, Slug, and Twist), commonly regulate the EMT process via modulating the expression levels of E-cadherin, N-cadherin, and vimentin [138–141], such that the Notch signaling pathway has been shown to be critical for the induction of EMT and the development of various diseases, including endometriosis [142,143]. Melatonin has been shown to inhibit Estradiol-17β-induced EMT in normal epithelial cells and endometriotic cells by increasing the expression of Numb and decreasing activity of the Notch signaling pathway [64]. Besides its anti-EMT effect on endometriosis, melatonin inhibited the EMT process and tumor progression in human gastric cancer cell lines by upregulating E-cadherin expression via the NF-κB signaling pathway [144,145]. A reduction in vimentin expression was equally observed when the rates of migration and invasion of mammary spheres formed by canine and human breast cancer cell lines were suppressed by NF-κB signaling after melatonin treatment [146]. Likewise, the Wnt/β-catenin pathway is another important regulator of EMT for β-catenin to interact with E-cadherin, which acts as a key factor for adhesive binding [139]. In a similar matter, melatonin can activate GSK3β via upregulating the Akt phosphorylation level to stimulate β-catenin metabolism, which ultimately inhibits EMT [147]. In addition, melatonin was found to suppress RSK2 via the HER2/MAPK/Erk pathway to inhibit EMT in breast cancer cells [148]. Besides these pathways, melatonin has also been shown to inhibit transforming growth factor beta-induced EMT in MG-63 osteosarcoma cells via the HIF-1/Snail/MMP-9 pathway [149].

3.6. Anti-Angiogenesis

Angiogenesis serves as a critical function during the development of endometriosis for facilitating the formation of new blood vessels to circulate nutrients and oxygen and to stimulate the progression of endometriotic lesions [150]. Activities of angiogenic factors, in particular vascular endothelial growth factor (VEGF), were higher in both peritoneal fluid and endometrium in women with endometriosis than controls [151,152]. The stimulation by VEGF can promote proliferation, migration, tubular organization, and increased permeability of endothelial cells, ultimately favoring angiogenesis [153]. Based a meta-analysis evaluating the treatment with inhibitors of VEGF/VEGFR agents in animal models of endometriosis, the capability to reduce the endometriotic lesion sizes without influencing the number of follicles was shown [154]. Similarly, a surgically induced endometriosis animal model demonstrated that suppression of the isoform of VEGF, notably VEGFC, can also suppress angiogenesis and the growth of endometriotic lesions [155,156]. In another study, melatonin was found to decrease the VEGF expression level for anti-angiogenic activity for reducing implant volumes in an endometriosis model [51]. Additionally, melatonin was also shown to regulate VEGF and VEGFR expression in physiological and pathological situations. In a breast cancer xenograft model, melatonin suppressed the expression of VEGFR-2, the most critical receptor of VEGF, to significantly reduce vascular density and angiogenesis [157], while in HUVECs, melatonin showed a dose-dependent inhibition of VEGFR-2 induced by VEGF [158]. In addition, oral administration of melatonin decreased serum VEGF levels in patients with metastatic cancer [159]. Additionally, in MCF-7 cells,
melatonin treatment reduced VEGF-C and VEGF receptors (VEGFR2 and VEGFR3) during hypoxia [134]. Several in vitro cancer studies demonstrated that melatonin interfered with hypoxia-inducible factor-1α (HIF-1α), which is the transcription factor and an upstream of VEGF. In a mouse model of renal cancer, the effect of melatonin on the expression of HIF-1α and VEGF was determined to be dependent on its antioxidant activity [159]. Likewise, melatonin reduced the growth of ectopic uterine tissue in an endometriosis rat model through the modulation of VEGF [51]. Furthermore, two vascular growth factors, angiopeptin-1 (Ang-1) and Ang-2, were noted to play crucial roles in angiogenesis. Their expressions in the eutopic endometrium of women with endometriosis were found to be increased when compared to normal uterine endometrium [160]. Melatonin lowered levels of ANG-1, ANG-2, and VEGF in the co-culture medium and their respective mRNA expressions in HUVEC and MCF-7 cell lines, respectively [45]. Unlike other angiogenic inhibitors solely targeting specific molecules, melatonin would act to alter several important angiogenic factors and processes to suppress vascularization in various diseases.

3.7. Immune Modulation

The immune system plays an important role in the pathophysiology and symptomatology of endometriosis [161,162]. Both the peripheral immune system and the eutopic endometrial immune situation were altered in women with endometriosis [163,164]. Unlike healthy individuals, macrophages (Mø), immature dendritic cells (DC), and regulatory T cells displayed different behaviors in women with endometriosis [165]. Besides immune cells, cytokines would also be altered in women suffering from endometriosis. Such cytokines as interleukin (IL) 6, IL-8, and cancer antigen (CA) 125 were shown to be upregulated, while tumor necrosis factor (TNF) α was found to be downregulated in patients with endometriosis. These alternations in the immune system would evidently reduce the immunological surveillance in endometriosis. Hence, the determination of these cytokines can often act as a diagnostic index of endometriosis [166,167]. In a mice study, the numbers of monocytes and natural killer (NK) cells were increased in those treated with either 7 or 14 days of melatonin [168]. Melatonin also enhanced antigen presentation via interaction between macrophages and T-lymphocytes, which can lead to the activation and proliferation of cytotoxic T lymphocytes [169]. In tumor-bearing rats, melatonin also showed its stimulatory potential on lymphocytes, monocytes/macrophages, and NK cells [170]. Recently, a meta-analysis analyzed 31 randomized and non-randomized placebo-controlled clinical trials with a total sample size of 1517 participants. It showed that melatonin supplementation significantly decreased TNF-α and IL-6 levels [171]. Taken together, melatonin has a direct immune regulatory effect in both animals and human studies.

3.8. Neurotrophic Effect

Pain is the most common symptom resulting from endometriosis. Endometriotic lesions cause chronic pelvic pain via compressing or infiltrating the nerves located close to the lesions [172]. Although the underlying mechanisms are elusive, emerging evidence has shown that endometriotic lesions and peritoneal fluid in women with endometriosis exhibit outstanding neurotrophic properties, including the increased expression of new nerve fibers, and the upregulation of various neurotrophies [173]. Brain-derived neurotrophic factor (BDNF), or abrineurin, is a member of the neurotrophic class of growth factors. This is a key regulator of neuronal survival and neurogenesis [174]. As reported, BDNF has the capacity to modulate pain pathways at different levels, from the peripheral nociceptors to spinal cord neurons and the brain [175]. A phase II clinical trial demonstrated that melatonin downregulated the secretion of BDNF to reduce pain scores as indexed by the visual analog scale (VAS) that includes daily pain, dysmenorrhea, dyspareunia, dysuria, and dyschezia. In addition, this study showed that melatonin treatment could be associated with an improved sleeping quality in patients with endometriosis [18]. Typically, melatonin has been suggested to be a well-tolerated alternative treatment for the pain-associated symptoms of endometriosis. In addition, melatonin possesses neuroprotective functions and is often
considered as a potential neurological drug in clinics, such that treatment with melatonin in newborn piglets increased hypothermic neuroprotection by improving brain energy metabolism and reducing brain damage [176]. It reduced the expression of astrogliosis, whose accumulation would trigger the production of pro-inflammatory cytokines leading to secondary damage [177]. In rat experimental models of neuropathic conditions, which include Alzheimer’s disease, Parkinson’s disease, and ischemic stroke, melatonin showed its effectiveness in arresting neurodegenerative phenomena [178]. Furthermore, during the dark phase, it appeared that mice with a higher melatonin level in plasma were less susceptible to a nociceptive stimulus [179]. The analgesic effects of melatonin were undeniable and evident, which had been documented in various animal models and clinical trials of patients with different pain syndromes. Animals treated with melatonin demonstrated its antinociceptive effect, thus alleviating the hypersensitivity induced in the hot plate test, electrical stimulation, and nerve ligation [180–182]. In clinical studies, melatonin reduced the frequency and intensity of pain in migraines, cluster headaches, tension headaches, chronic back pain, and fibromyalgia [183–187]. Considering the therapeutic application of melatonin from both its neuroprotective and antinociceptive functions, melatonin should be considered as a potential drug for treating endometriosis-associated pain.

4. Clinical Insights of Melatonin in Endometriosis and Other Reproductive Diseases

Currently, there are many ongoing clinical studies on using melatonin as a therapeutic strategy, including insomnia, diabetes, fibromyalgia, hypertension, anticancer, and aging-related diseases, such as Parkinson’s and Alzheimer’s disease [188–191]. In the obstetrics and gynecology discipline, there was only one randomized controlled trial in melatonin for endometriosis in 2013. For other reproductive disorders, melatonin has shown its clinical therapeutic values in various aspects (Table 2). Based on a clinical trial, it was shown that melatonin supplements could relieve pelvic pain and improve the sleeping quality of women with endometriosis [18]. During application for IVF-ET with infertile patients, the administration of melatonin can improve the oocyte quality [192]. The number of degenerated oocytes was significantly reduced in the 3 mg melatonin group when compared to those in the control group [193]. Additionally, the number of fertilized embryos was also shown to have an increased tendency in the 3 mg melatonin group [194]. Likewise, intrafollicular melatonin concentrations were slightly increased in the 1 mg melatonin group, and concentrations were further increased in the 3 mg melatonin group. After treatment of melatonin, the concentration of intrafollicular lipid peroxide, a free-radical reaction that causes injury to oocytes, showed a tendency towards a lower level, the level of significance being dependent on melatonin dosage [195]. Melatonin increased follicular concentrations of it, thereby inhibiting oxidative stress and improving the quality of oocytes [195]. A further study also examined the possibility of whether melatonin therapy inhibited oxidative stress to improve the quality of oocytes and the clinical outcome of IVF-ET [196]. The result in this study reported improved concurrent fertilization and pregnancy rates with melatonin treatment [196]. These initial studies inspired other researchers to examine whether the use of melatonin can help to increase the number of mature oocytes for improving the fertilization rate and the clinical outcome of IVF-ET. In general, melatonin supplementation was shown to increase the number and quality of both oocytes and embryos. Moreover, it could increase the clinical pregnancy rates of patients with infertility disorders or low fertility rates [47,192,195,197]. As poor oocyte quality is a major cause of infertility in endometriosis, whether melatonin can increase the fertility rate through improving oocyte qualities requires further studies. In addition, treatment with melatonin was able to restore menstrual cyclicity in women with polycystic ovarian syndrome (PCOS) [198]. Daily supplementation of melatonin in PCOS women showed a significant improvement in pregnancy rates [199]. Importantly, the overall effects of melatonin supplementation in fetal growth restriction, pre-eclampsia, and climacteric symptoms appear to be promising and clinically relevant [200–202]. Likewise, women with endometriosis also have menstrual and poor obstetrics outcomes as summarized in Table 2.
Table 2. Clinical trials of melatonin for endometriosis and other female reproduction.

| Studies         | Disorder    | Sample Size (Melatonin/Control) | Age (Means ± SD/SEM or Range) | Daily Dose | Duration or Period                      | Main Outcomes                                                                 | Adverse Events | Trial Registration Number |
|-----------------|-------------|---------------------------------|------------------------------|------------|----------------------------------------|--------------------------------------------------------------------------------|----------------|--------------------------|
| Schwertner 2013 [18] | Endometriosis | 20/20                           | 18–45                        | 10 mg      | 8 weeks                                | Reduced pain scores and BDNF levels Increased sleep quality                     | /              | /                        |
| Takasaki 2003 [195] | Infertility  | 27/NA                           | 34 ± 4.4                     | 1 or 3 mg  | From 2nd to 5th day of the menstrual cycle to hCG day | Decreased number of degenerate oocytes (only in 3 mg group)                      | /              | /                        |
| Tamura 2008 [47]  | Infertility  | 56/59                           | 34.8 ± 4.8                   | 3 mg       | From 2nd to 5th day of the menstrual cycle to OPU day | Increased oocytes quality and fertility rate                                     | /              | /                        |
| Rizzo 2010 [203]  | Infertility  | 32/33                           | 35–42                        | 3 mg       | From GnRH administration day to pregnancy test result was confirmed | Increased tendency on number of mature oocytes, embryo quality, clinical pregnancy rate, and implantation rate | /              | /                        |
| Batioglu 2012 [193] | Infertility  | 40/45                           | 20–40                        | 3 mg       | During the IVF-ET procedure            | Increased number and percentage of mature oocytes Increased number of embryos of top quality Increased tendency on clinical pregnancy rate | /              | /                        |
| Nishihara 2014 [204] | Infertility  | 97/NA                           | ≤42                          | 3 mg       | At least 2 weeks                       | Increased fertilization and embryo quality                                      | /              | /                        |
| Fernando 2018 [205] | Infertility  | 32/29 29/29 26/29              | 18–45                        | 2, 4, or 8 mg | From 2nd to 5th day of the menstrual cycle to OPU day | No significant differences in daytime Karolinska sleepiness score between groups No differences in objective measures of sleep quantity or quality Improved the subjective sleep quality scores except 8 mg group | /              | ACTRN12613001317785     |
| Studies          | Disorder                        | Sample Size (Melatonin/Control) | Age (Means ± SD/SEM or Range) | Daily Dose | Duration or Period                                      | Main Outcomes                                                                 | Adverse Events                                      | Trial Registration Number |
|------------------|---------------------------------|---------------------------------|-------------------------------|------------|--------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------|--------------------------|
| Fernando 2018 [194] | Infertility                     | 41/41 39/41 40/41               | 18–45                         | 2, 4, or 8 mg | From 2nd to 5th day of the menstrual cycle to OPU day | There were no differences between all the groups in total oocyte number, number of MII oocytes, number of fertilized oocytes, the number or quality of embryos, clinical pregnancy rate, or live birth rate | Headache, fatigue (no significant difference)         | ACTRN12613001317785     |
| Espino 2019 [196]  | Infertility                     | 20/20                           |                               | 3 or 6 mg   | From 2nd to 5th day of the menstrual cycle to OPU day | Ameliorated intrafollicular oxidative balance and oocyte quality Increased the rate of pregnancies/live births No significant difference between 3 mg group and 6 mg group | / /                                  | / /                     |
| Wdowiak 2020 [206] | Infertility                     | 50/50                           | 20–35                         | 1 mg        | 6 months                                                | Increased blastocyst and oocyte quality Increased rate of clinical pregnancy | / /                                                  | / /                     |
| Jahromi 2017 [207] | Diminished ovarian reserve      | 40/40                           | 22–42                         | 3 mg        | From 2nd to 5th day of the menstrual cycle to OPU day | Increased serum estradiol level on the triggering day Increased number of MII oocytes, top quality embryos with G1 and G2 | / /                                                  | IRCT2014041417264N1    |
| Tagliaferri 2017 [198] | PCOS                           | 40/NA                           | 23.25 ± 4.07                  | 2 mg        | 6 months                                                | Improved the menstrual irregularities Decreased biochemical hyperandrogenism | / /                                                  | / /                     |
| Mokhtari 2019 [199] | PCOS                            | 98/100                          | 28.9 ± 5.5                    | 3 mg        | From 2nd to 5th day of the menstrual cycle to hCG day  | Increased chemical pregnancies and endometrial thickness | / /                                                  | / /                     |
| Parandavar 2018 [208] | Menopausal women               | 98/142                          | 53.22 ± 4.21                  | 3 mg        | 3 months                                                | Increased amount of triglyceride | / /                                                  | / /                     |
| Studies                  | Disorder                              | Sample Size (Melatonin/Control) | Age (Means ± SD/SEM or Range) | Daily Dose | Duration or Period | Main Outcomes                                                                 | Adverse Events                                                                 | Trial Registration Number |
|-------------------------|---------------------------------------|---------------------------------|-------------------------------|------------|-------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------------|
| Chojnacki 2018 [209]    | Postmenopausal women                  | 30/30                           | 51–64                         | 8 mg       | 12 months         | Decreased Kupfferman Index and body mass index                                | No adverse influence on patients’ psychosomatic activity                      | /                        |
| Miller 2014 [200]       | Fetal growth restriction              | 6/6                             | /                             | 8 mg       | For the duration of pregnancy | Decreased placental oxidative stress                                         | No adverse maternal or fetal effects                                         | NCT01695070              |
| Parandavar 2014 [202]   | Climacteric symptoms                 | 99/101                          | 40–60                         | 3 mg       | 3 months          | Decreased climacteric symptoms score                                         | Sleepiness, nausea, vomiting, and headache (no significant difference)       | /                        |
| Hobson 2018 [201]       | Preeclampsia                          | 20/48                           | Control: 30.6 ± 0.8 Melatonin: 32.7 ± 1.1 | 30 mg  | From recruitment until delivery | No adverse events and adverse drug reactions Prolonged gestation Reduced the pharmacological need for antihypertensives | No adverse events / ACTRN, Australian clinical trials registration number; BDNF, Brain-derived neurotrophic factor; hCG, Human chorionic gonadotropin; GnRH, Gonadotropin-releasing hormone; IRCT, Iranian Registry of Clinical Trials; IVF-ET, In vitro fertilization and embryo transfer; MII, Metaphase II; NA, Not applicable; NCT, National clinical trial; OPU, Oocyte pick up; PCOS, Polycystic ovary syndrome; SD, Standard deviation; SEM, Standard error of mean; SOD, Superoxide dismutase. | / |
Therapeutic strategies that are safe and with minimal reproductive side effects are essential to women with endometriosis. Melatonin is believed to be a potential candidate as a safe supplementation toward treating endometriosis and endometriosis-associated symptoms [210]. Owing to the limited clinical trials of melatonin in endometriosis, the other clinical trials utilizing melatonin as a potential therapeutic solution on other reproductive diseases may help to support its application toward endometriosis.

5. Conclusions

Importantly, this review has helped to indicate the potential therapeutic capabilities of melatonin for the treatment of endometriosis and its associated symptoms. This is attributed to its many properties, including antioxidation and anti-inflammation, its ability to modulate the endocrine functions via hormonal signaling pathways, and the absence of toxic side effects. Additionally, there is accumulating evidence which illustrates the application of exogenous melatonin to suppress ectopic endometriotic lesions, relieve endometriosis-associated pelvic pain, and enhance the sleeping quality of women with endometriosis. Nevertheless, further analysis on determining the melatonin levels in the eutopic and ectopic endometrium of women with endometriosis for therapeutic efficacy is still warranted. Moreover, corroborating evidence from mechanistic studies and randomized controlled trials would be necessary for better understanding the pharmakinetics and the clinical application of melatonin for endometriosis treatment.

Author Contributions: Conceptualization, Y.L., T.Z. and C.-C.W.; data curation, Y.L. and R.Z.; writing—original draft preparation, Y.L. and S.-W.H.; writing—review and editing, J.P.-W.C., G.C.-W.M., L.F. and C.-C.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Cavallo, A. Melatonin and human puberty: Current perspectives. J. Pineal Res. 1993, 15, 115–121. [CrossRef]
2. Cagnacci, A. Melatonin in relation to physiology in adult humans. J. Pineal Res. 1996, 21, 200–213. [CrossRef] [PubMed]
3. Malpau, B.; Daveau, A.; Maurice-Mandon, F.; Duarte, G.; Chemineau, P. Evidence That Melatonin Acts in the Premammillary Hypothalamic Area to Control Reproduction in the Ewe: Presence of Binding Sites and Stimulation of Luteinizing Hormone Secretion by in Situ Microimplant Delivery. Endocrinology 1998, 139, 1508–1516. [CrossRef]
4. Gingerich, S.; Wang, X.; Lee, P.; Dhillon, S.; Chalmers, J.; Koletar, M.; Belsham, D. The generation of an array of clonal, immortalized cell models from the rat hypothalamus: Analysis of melatonin effects on kisspeptin and gonadotropin-inhibitory hormone neurons. Neuroscience 2009, 162, 1134–1140. [CrossRef]
5. Acuña-Castroviejo, D.; Escames, G.; Venegas, C.; Diaz-Casado, M.E.; Lima-Cabello, E.; Lopez, L.C.; Rosales-Corral, S.; Tan, D.-X.; Reiter, R.J. Extraneopineal melatonin: Sources, regulation, and potential functions. Cell. Mol. Life Sci. 2014, 71, 2997–3025. [CrossRef] [PubMed]
6. Pang, S.; Li, L.; Ayre, E.; Pang, C.; Lee, P.; Xu, R.; Chow, P.; Yu, Z.; Shiu, S. Neuroendocrinology of melatonin in reproduction: Recent developments. J. Chem. Neuroanat. 1998, 14, 157–166. [CrossRef]
7. Yellon, S.M.; Longo, L.D. Melatonin rhythms in fetal and maternal circulation during pregnancy in sheep. Am. J. Physiol. Metab. 1987, 252, E799–E802. [CrossRef] [PubMed]
8. Showell, M.G.; Mackenzie-Proctor, R.; Jordan, V.; Hart, R.J. Antioxidants for female subfertility. Cochrane Database Syst. Rev. 2020, 2020, 8. [CrossRef]
9. Hardeland, R.; Cardinali, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin—A pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93, 350–384. [CrossRef]
10. Bulun, S.; Yilmaz, B.D.; Sisson, C.; Miyazaki, K.; Bernardi, L.; Liu, S.; Kohlmeier, A.; Yin, P.; Milad, M.; Wei, J. Endometriosis. Endocr. Rev. 2019, 40, 1048–1079. [CrossRef]
11. Horne, A.W.; Saunders, P. SnapShot: Endometriosis. Cell 2019, 179, 1677–1677.e1. [CrossRef] [PubMed]
12. Zondervan, K.T.; Becker, C.M.; Missmer, S.A. Endometriosis. N. Engl. J. Med. 2020, 382, 1244–1256. [CrossRef]
42. Mehrzadi, S.; Safa, M.; Kamrava, S.K.; Darabi, R.; Hayat, P.; Motievalian, M. Protective mechanisms of melatonin against hydrogen-peroxide-induced toxicity in human bone-marrow-derived mesenchymal stem cells. *Can. J. Physiol. Pharmacol.* 2017, 95, 773–786. [CrossRef] [PubMed]

43. Chuffa, L.G.; Alves, M.; Martínez, M.; Camargo, I.C.C.; Pinheiro, P.F.F.; Domeniconi, R.F.; Júnior, L.A.L.; Martínez, F.E. Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma. *Endocr. Relat. Cancer* 2015, 23, 65–76. [CrossRef] [PubMed]

44. Cuesta, S.; Kireev, R.; Forman, K.; García, C.; Escames, G.; Ariznavarretta, C.; Vara, E.; Tresguerres, J.A. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). *Exp. Gerontol.* 2010, 45, 950–956. [CrossRef] [PubMed]

45. González-González, A.; González, A.; Alonso-González, C.; Menéndez-Menéndez, J.; Martínez-Campa, C.; Cos, S. Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF in co-cultures of human endothelial and breast cancer cells. *Oncol. Rep.* 2017, 39, 433–441. [CrossRef]

46. Tamura, H.; Nakamura, Y.; Terron, M.P.; Flores-Alvarado, I.J.; Manchester, L.C.; Tan, D.-X.; Sugino, N.; Reiter, R.J. Melatonin and pregnancy in the human. *Reprod. Toxicol.* 2008, 25, 291–303. [CrossRef]

47. Tamura, H.; Takasaki, A.; Miwa, I.; Taniguchi, K.; Maekawa, R.; Asada, H.; Taketani, T.; Matsuoka, A.; Yamagata, Y.; Shimamura, K.; et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. *J. Pineal Res.* 2007, 44, 280–287. [CrossRef]

48. Song, G.; Yoon, K.-A.; Chi, H.; Roh, J.; Kim, J.-H. Decreased concentration of serum melatonin in nighttime compared with daytime female medical technology students in South Korea. *Chronobiol. Int.* 2016, 33, 1305–1310. [CrossRef]

49. Marino, J.L.; Holt, V.L.; Chen, C.; Davis, S. Shift Work, hCLOCK T3111C Polymorphism, and Endometriosis Risk. *Epidemiology* 2008, 19, 477–484. [CrossRef]

50. Cetinkaya, N.; Attar, R.; Yildirim, G.; Ficicioglu, C.; Ozkan, F.; Yilmaz, B.; Yesildaglar, N. The effects of different doses of melatonin treatment on endometrial implants in an oophorectomized rat endometriosis model. *Arch. Gynecol. Obstet.* 2014, 291, 591–598. [CrossRef]

51. Yilmaz, B.; Kilic, S.; Aksakal, O.; Ertas, I.E.; Aksoy, Y.; Lortlar, N.; Kelekci, S.; Gungor, T. Melatonin causes regression of endometriotic implants in rats by modulating angiogenesis, tissue levels of antioxidants and matrix metalloproteinases. *Arch. Gynecol. Obstet.* 2014, 292, 209–216. [CrossRef]

52. Yıldırım, G.; Attar, R.; Ozkan, F.; Kumbak, B.; Ficicioglu, C.; Yesildaglar, N. The effects of letrozole and melatonin on surgically induced endometriosis in a rat model: A preliminary study. *Fertil. Steril.* 2010, 93, 1787–1792. [CrossRef] [PubMed]

53. Mosher, A.A.; Tsoulis, M.W.; Lim, J.; Tan, C.; Agarwal, S.; Leyland, N.A.; Foster, W.G. Melatonin activity and receptor expression in endometrial tissue and endometriosis. *Hum. Reprod.* 2019, 34, 1215–1224. [CrossRef] [PubMed]

54. Barchas, J.; Dacosta, F.; Spector, S. Acute Pharmacology of Melatonin. *Nature* 1967, 214, 919–920. [CrossRef]

55. Cavalcante, A.G.D.M.; De Bruin, P.F.C.; De Bruin, V.M.S.; Nunes, D.M.; Pereira, E.D.B.; Cavalcante, M.M.; Andrade, G.M. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled study. *J. Pineal Res.* 2012, 53, 238–244. [CrossRef]

56. Nickkhohlg, A.; Schneider, H.; Sobirey, M.; Venetz, W.P.; Hinz, U.; Pelzl, L.H.; Gotthardt, D.N.; Cekauskas, A.; Manikas, M.; Mikalauskas, S.; et al. The use of high-dose melatonin in liver resection is safe: First clinical experience. *J. Pineal Res.* 2011, 50, 381–388. [CrossRef]

57. Genario, R.; Morelo, E.; Bueno, A.A.; Santos, H.O. The usefulness of melatonin in the field of obstetrics and gynecology. *Pharmacol. Res.* 2019, 147, 104337. [CrossRef]

58. Güney, M.; Oral, B.; Karahan, N.; Mungan, T. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. *Fertil. Steril.* 2008, 89, 934–942. [CrossRef] [PubMed]

59. Paul, S.; Sharma, A.V.; Das Mahapatra, P.; Bhattacharya, P.; Reiter, R.J.; Swarnakar, S. Role of melatonin in regulating matrix metalloproteinase-9 via tissue inhibitors of metalloproteinase-1 during protection against endometriosis. *J. Pineal Res.* 2008, 44, 439–449. [CrossRef]

60. Paul, S.; Bhattacharya, P.; Das Mahapatra, P.; Swarnakar, S. Melatonin protects against endometriosis via regulation of matrix metalloproteinase-3 and an apoptotic inhibitor. *J. Pineal Res.* 2010, 49, 156–168. [CrossRef]

61. Yıldırım, G.; Attar, R.; Fıçıcıoğlu, C.; Karateke, A.; Ozkan, F.; Kilic, E.; Yilmaz, B.; Yeşildaglar, N. The combination of letrozole and melatonin causes regression in size not histopathological scores on endometriosis in an experimental rat model. *J. Turk. Gynecol. Assoc.* 2009, 10, 199–204.

62. Koc, O.; Gunduz, B.; Topcuoglu, A.; Bugdayci, G.; Yilmaz, F.; Duran, B. Effects of pinealectomy and melatonin supplementation on endometrioma in a rat model. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2010, 153, 72–76. [CrossRef]

63. Kocadal, N.C.; Attar, R.; Yıldırım, G.; Fıçıcıoğlu, C.; Ozkan, F.; Yilmaz, B.; Yeşildaglar, N. Melatonin treatment results in regression of endometriotic lesions in an oophorectomized rat endometriosis model. *J. Turk. Gynecol. Assoc.* 2013, 14, 81–86. [CrossRef] [PubMed]

64. Qi, S.; Yan, L.; Liu, Z.; Mu, Y.-L.; Li, M.; Zhao, X.; Chen, Z.-J.; Zhang, H. Melatonin inhibits 17β-estradiol-induced migration, invasion and epithelial-mesenchymal transition in normal and endometriotic endometrial epithelial cells. *Reprod. Biol. Endocrinol.* 2018, 16, 62. [CrossRef] [PubMed]

65. Scutiero, G.; Iannone, P.; Bernardi, G.; Bonaccorsi, G.; Spadaro, S.; Volta, C.A.; Greco, P.; Nappi, L. Oxidative Stress and Endometriosis: A Systematic Review of the Literature. *Oxid. Med. Cell. Longev.* 2017, 2017, 7265238. [CrossRef] [PubMed]
66. Donnez, J.; Bindia, M.M.; Donnez, O.; Dolmans, M.-M. Oxidative stress in the pelvic cavity and its role in the pathogenesis of endometriosis. Fertil. Steril. 2016, 106, 1011–1017. [CrossRef]

67. Yesildağlar, N.; Yıldırım, G.Y.; Atlar, R.; Ozkan, F.; Akkaya, H.; Yilmaz, B. The effects of melatonin on endometriotic lesions induced by implanting human endometriotic cells in the first SCID-mouse endometriosis-model developed in Turkey. Clin. Exp. Obstet. Gynecol. 2016, 43, 25–30. [CrossRef]

68. Harald, R. Antioxidative Protection by Melatonin: Multiplicity of Mechanisms from Radical Detoxification to Radical Avoidance. Endocrine 2005, 27, 119–130. [CrossRef]

69. Tan, D.-X.; Manchester, L.C.; Terron, M.P.; Flores-Alvarado, I.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with oxygen and nitrogen species? J. Pineal Res. 2006, 42, 28–42. [CrossRef]

70. Richter, H.G.; Hansel, J.A.; Raut, S.; Giussani, D.A. Melatonin improves placental efficiency and birth weight and increases the placental expression of antioxidant enzymes in undernourished pregnancy. J. Pineal Res. 2009, 46, 357–364. [CrossRef]

71. Mori, T.; Ito, F.; Koshiba, A.; Kataoka, H.; Takaoka, O.; Okimura, H.; Khan, K.N.; Kitawaki, J. Local estrogen formation and its regulation in endometriosis. Reprod. Med. Biol. 2019, 18, 305–311. [CrossRef] [PubMed]

72. Han, S.J.; O’Malley, B.W. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum. Reprod. Updat. 2014, 20, 467–484. [CrossRef]

73. Tang, Z.-R.; Zhang, R.; Lian, Z.-X.; Deng, S.-L.; Yu, K. Estrogen-Receptor Expression and Function in Female Reproductive Disease. Cells 2019, 8, 1123. [CrossRef] [PubMed]

74. Pellegrini, C.; Gori, I.; Achtari, C.; Hornung, D.; Chardonnens, E.; Wunder, D.; Fiche, M.; Canny, G.O. The expression of estrogen receptors as well as GReB1, c-MYC, and cyclin D1, estrogen-regulated genes implicated in proliferation, is increased in peritoneal endometriosis. Fertil. Steril. 2012, 98, 1200–1208. [CrossRef] [PubMed] 2012, 98, 1200–1208. [CrossRef] [PubMed]

75. Chantalat, E.; Valera, M.-C.; Vaysse, C.; Noirrit, E.; Rusidze, M.; Weyl, A.; Vergiere, K.; Buscaill, E.; Lluel, P.; Fontaine, C.; et al. Estrogen Receptors and Endometriosis. Int. J. Mol. Sci. 2020, 21, 2815. [CrossRef]

76. Patel, B.G.; Rudnicki, M.; Yu, J.; Shu, Y.; Taylor, R.N. Progesterone resistance in endometriosis: Origins, consequences and interventions. Acta Obstet. Gynecol. Scand. 2017, 96, 623–632. [CrossRef]

77. Attia, G.R.; Zeitoun, K.; Edwards, D.; Johns, A.; Carr, B.R.; Bulun, S.E. Progesterone Receptor Isoform A But Not B Is Expressed in human endometrium and oxygen and nitrogen species? J. Pineal Res. 2006, 42, 28–42. [CrossRef]

78. Flores, V.; Vanhie, A.; Dang, T.; Taylor, H.S. Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis. J. Clin. Endocrinol. Metab. 2010, 85, 2897–2902. [CrossRef]

79. Liang, B.; Wu, L.; Xu, H.; Cheung, C.W.; Fung, W.Y.; Wong, S.W.; Wang, C.C. Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: A comparison study in mice. Reprod. Biol. Endocrinol. 2018, 16, 32. [CrossRef]

80. Cipolla-Neto, J.; Amaral, F.G.; Soares, J.M., Jr.; Gallo, C.C.; Furtado, A.; Cavaco, J.E.; Gonçalves, I.; Santos, C.R.A.; Quintela, T. The effects of melatonin on endometriotic lesions in mice. Fertil. Steril. 2016, 106, 1011–1017. [CrossRef]

81. Tamura, H.; Nakamura, Y.; Takiguchi, S.; Kashida, S.; Yamagata, Y.; Sugino, N.; Kato, H. Melatonin directly suppresses steroid production by preovulatory follicles in the cyclic hamster. J. Pineal Res. 1998, 25, 135–141. [CrossRef] [PubMed]

82. Chuffa, L.G.; Seiva, F.R.; Franci, J.A.; et al. Melatonin reduces LH, 17 beta-estradiol and induces differential regulation of sex steroid receptors in reproductive tissues during rat ovulation. Reprod. Biol. Endocrinol. 2011, 9, 108. [CrossRef] [PubMed]

83. Yesildaglar, N.; Yıldırım, G.Y.; Attar, R.; Ozkan, F.; Akkaya, H.; Yilmaz, B. The effects of melatonin on endometriotic lesions induced by implanting human endometriotic cells in the first SCID-mouse endometriosis-model developed in Turkey. Clin. Exp. Obstet. Gynecol. 2016, 43, 25–30. [CrossRef]

84. Cos, S.; Sánchez-Barceló, E.J. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol. Histopathol. 2000, 15, 637–647. [CrossRef] [PubMed]

85. González, A. Melatonin: An Endogenous Antiestrogen with Oncostatic Properties. In Melatonin From Molecules to Therapy; Nova Science Publishers Inc.: New York, NY, USA, 2007; pp. 261–272.

86. Hill, S.M.; Spriggs, L.L.; Simon, M.A.; Muraoka, H.; Blask, D.E. The growth inhibitory action of melatonin on human breast cancer cells. Breast Cancer Res. Treat. 1995, 37, 43–52. [CrossRef] [PubMed]

87. Bódis, J.; Koppán, M.; Kornya, L.; Tinneberg, H.; Török, A. Influence of Melatonin on Basal and Gonadotropin-Stimulated Progesterone and Estradiol Secretion of Cultured Human Granulosa Cells and in the Superfused Granulosa Cell System. Gynecol. Obstet. Investig. 2001, 52, 198–202. [CrossRef]

88. Cheng, J.-C.; Fang, L.; Li, Y.; Wang, S.; Li, Y.; Yan, Y.; Jia, Q.; Wu, Z.; Wang, Z.; Han, X.; et al. Melatonin stimulates aromatase expression and estradiol production in human granulosa-lutein cells: Relevance for high serum estradiol levels in patients with ovarian hyperstimulation syndrome. Exp. Mol. Med. 2020, 52, 1341–1350. [CrossRef]

89. Chen, S.; Besman, M.J.; Sparkes, R.S.; Zollman, S.; Klisak, I.; Mohandas, T.; Hall, P.F.; Shively, J.E. Human Aromatase: cDNA Cloning, Southern Blot Analysis, and Assignment of the Gene to Chromosome 15. DNA Cell Biol. 1988, 7, 27–38. [CrossRef]

90. González, A.; Martínez-Campa, C.; Mediavilla, M.D.; Alonso-González, C.; Sánchez-Mateos, S.; Hill, S.M.; Sánchez-Barceló, E.J.; Cos, S. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol. Rep. 2007, 17, 947–953. [CrossRef]
91. Martínez-Campa, C.M.; González, M.; Mediavilla, M.D.; Alonso-González, C.; Alvarezgarcía, V.; Sanchez-Barcelo, E.J.; Cos, S. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br. J. Cancer 2009, 101, 1613–1619. [CrossRef]

92. Alvarez-García, V.; González, A.; Martínez-Campa, C.; Alonso-González, C.; Cos, S. Melatonin modulates aromatase activity and expression in endothelial cells. Oncol. Rep. 2013, 29, 2058–2064. [CrossRef] [PubMed]

93. Gonzalez, A.; Martínez-Campa, C.M.; Mediavilla, M.D.; Alonso-González, C.; Sanchez-Barcelo, E.J.; Cos, S. Inhibitory effects of pharmacological doses of melatonin on aromatase expression and activity in rat glioma cells. Br. J. Cancer 2007, 97, 755–760. [CrossRef] [PubMed]

94. Simpson, E.R.; Misso, M.; Hewitt, K.N.; Hill, R.; Boon, W.C.; Jones, M.; Kovacic, A.; Zhou, J.; Clyne, C.D. Estrogen—The Good, the Bad, and the Unexpected. Endocr. Rev. 2005, 26, 322–330. [CrossRef] [PubMed]

95. Chen, D.; Reierstad, S.; Lu, M.; Lin, Z.; Ishikawa, H.; Bulun, S.E. Regulation of breast cancer-associated aromatase promoters. Cancer Lett. 2009, 273, 15–27. [CrossRef]

96. Dardes, R.C.; Baracat, E.C.; Simões, M.J. Modulation of estrous cycle and LH, FSH and melatonin levels by pinealectomy and sham-pinealectomy in female rats. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2000, 24, 441–453. [CrossRef]

97. Webley, G.E.; Luck, M.R. Melatonin directly stimulates the secretion of progesterone by human and bovine granulosa cells in vitro. Reproduction 1986, 78, 711–717. [CrossRef]

98. Fang, L.; Li, Y.; Wang, S.; Yu, Y.; Li, Y.; Guo, Y.; Yan, Y.; Sun, Y.-P. Melatonin induces progesterone production in human granulosa-lutein cells through upregulation of STAR expression. Aging 2019, 11, 9013–9024. [CrossRef]

99. Schaeffer, H.-J.; Sirotkin, A.V. Melatonin and serotonin regulate the release of insulin-like growth factor-I, oxytocin and progesterone by cultured human granulosa cells. Exp. Clin. Endocrinol. Diabetes 1997, 105, 109–112. [CrossRef]

100. Woo, M.M.M.; Tai, C.-J.; Kang, S.K.; Nathwani, P.S.; Pang, S.F.; Leung, P. Direct Action of Melatonin in Human Granulosa-Luteal Cells. J. Clin. Endocrinol. Metab. 2001, 86, 4789–4797. [CrossRef]

101. Taketani, T.; Tamura, H.; Takasaki, A.; Lee, L.; Kizuka, F.; Tamura, I.; Taniguchi, K.; Maekawa, R.; Asada, H.; Shimamura, K.; et al. Protective role of melatonin in the development of human luteinized granulosa cells. J. Pineal Res. 2011, 51, 207–213. [CrossRef]

102. Wang, X.; Meng, K.; He, Y.; Wang, H.; Zhang, Y.; Quan, F. Melatonin Stimulates STAR Expression and Progesterone Production via Activation of the P38/akt Pathway in Bovine Theca Cells. Int. J. Biol. Sci. 2019, 15, 404–415. [CrossRef] [PubMed]

103. Yang, M.; Guan, S.; Tao, J.; Zhu, K.; Lv, D.; Wang, J.; Li, G.; Gao, Y.; Wu, H.; Liu, J.; et al. Melatonin promotes male reproductive performance and increases testosterone synthesis in mammalian Leydig cells. Biol. Reprod. 2021, 104, 1322–1336. [CrossRef] [PubMed]

104. Ezzati, M.; Roshangar, L.; Soleimani, M.; Parvizi, M.; Kiani, M.; Kargar, S.; Maghsoudi, N.; Kianpour, F.; Mirnejad, M.; et al. Melatonin and vitamin D3 synergistically inhibit motility and invasiveness in HepG2 liver cancer cells. Oncotarget 2015, 7, 2985–3001. [CrossRef]

105. Ram, P.; Yuan, L.; Dai, J.; Kifer, T.; Klotz, D.M.; Spriggs, L.L.; Hill, S.M. Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. J. Pineal Res. 2000, 28, 210–218. [CrossRef] [PubMed]

106. Chuffa, L.G.D.A.; Lupi, L.A.; Cucielo, M.S.; Silveira, H.S.; Reiter, R.J.; Seiva, F.R.F. Melatonin Promotes Uterine and Placental Health: Potential Molecular Mechanisms. Int. J. Mol. Sci. 2019, 21, 300. [CrossRef]

107. Sainz, R.M.; Mayo, J.C.; Rodriguez, C.; Tan, D.X.; Lopez-Burillo, S.; Reiter, R.J. Melatonin and cell death: Differential actions on apoptosis in normal and cancer cells. J. Cell Physiol. 2000, 183, 20–30. [CrossRef]

108. Vermeulen, K.; Berneman, Z.N.; Van Bockstaele, D.R. Cell cycle and apoptosis. Cell Prolif. 2000, 29, 873–878. [CrossRef] [PubMed]

109. Alvarez-Garcia, V.; Gonzalez, A.; Martinez-Campa, C.; Alonso-Gonzalez, C.; Cos, S. Melatonin modulates aromatase activity and expression in endothelial cells. Oncol. Rep. 2013, 29, 2058–2064. [CrossRef] [PubMed]

110. Ordoñez, R.; Carbajo-Pescador, S.; Prieto-Domínguez-Campa, C.M.; González-Gallo, J.; Mauriz, J.L. Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J. Pineal Res. 2013, 56, 20–26. [CrossRef]

111. Wang, J.; Xiao, Z.; Zhang, Y.; Shi, D.; Chen, W.; Fu, L.; Liu, L.; Xie, F.; Kang, T.; Huang, W.; et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J. Pineal Res. 2012, 53, 77–90. [CrossRef]

112. Proietti, S.; Cucina, A.; D’Anselmi, F.; DiNicola, S.; Pasqualeto, A.; Lisi, E.; Bizzarri, M. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ1-dependent growth inhibition of breast cancer cells. J. Pineal Res. 2010, 50, 150–158. [CrossRef] [PubMed]

113. Pizarro, J.G.; Yeste-Velasco, M.; Esparza, J.L.; Verdaguer, E.; Pallols, M.; Camins, A.; Folch, J.; Pallàs, M.; Esparza, J.L. The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes. J. Pineal Res. 2008, 45, 8–16. [CrossRef] [PubMed]

114. Cini, G.; Neri, B.; Pacini, A.; Cesati, V.; Sassoli, C.; Quattrone, S.; D’Apolito, M.; Fazio, A.; Scapagnini, G.; Provenzani, A.; et al. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: A molecular basis for melatonin-induced oncostatic effects. J. Pineal Res. 2005, 39, 12–20. [CrossRef] [PubMed]

115. Liu, L.; Xu, Y.; Reiter, R.J. Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. Bone 2013, 55, 432–438. [CrossRef] [PubMed]

116. Mortezae, K.; Najafi, M.; Farhood, B.; Ahmadi, A.; Potes, Y.; Shabeeb, D.; Musa, A.E. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. Life Sci. 2019, 228, 228–241. [CrossRef] [PubMed]
Klemmt, P.A.; Carver, J.G.; Koninckx, P.; McVeigh, E.J.; Mardon, H.J. Endometrial cells from women with endometriosis have increased adhesion and proliferative capacity in response to extracellular matrix components: Towards a mechanistic model for endometriosis progression. *Hum. Reprod.* 2007, 22, 3139–3147. [CrossRef]

Rai, V.; Hopkisson, J.; Kennedy, S.; Bergqvist, A.; Barlow, D.H.; Mardon, H.J. Integrins alpha 3 and alpha 6 are differentially expressed in endometrium and endometriosis. *J. Pathol.* 1996, 180, 181–187. [CrossRef]

Han, Y.-S.; Lee, J.H.; Lee, S.H. Melatonin suppresses ischemia-induced fibrosis by regulating miR-149. *Biochem. Biophys. Res. Commun.* 2020, 525, 354–359. [CrossRef]

Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. *Nat. Cancer* 2002, 2, 161–174. [CrossRef]

Chung, H.-W.; Wen, Y.; Chun, S.-H.; Nezhat, C.; Woo, B.-H.; Polan, M.L. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: A rationale for endometriotic invasiveness. *Fertil. Steril.* 2001, 75, 152–159. [CrossRef]

Shaco-Levy, R.; Sharabi, S.; Benharroch, D.; Piura, B.; Sion-Vardy, N. Matrix metalloproteinases 2 and 9, E-cadherin, and β-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2008, 139, 226–232. [CrossRef] [PubMed]

Di Carlo, C.; Bonifacio, M.; Tommaselli, G.A.; Bifulco, G.; Guerra, G.; Nappi, C. Metalloproteinases, vascular endothelial growth factor, and angiopoietin 1 and 2 in eutopic and ectopic endometrium. *Fertil. Steril.* 2009, 91, 2315–2323. [CrossRef] [PubMed]

Collette, T.; Meaux, R.; Mailloux, J.; Akoum, A. Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis. *Hum. Reprod.* 2006, 21, 3059–3067. [CrossRef] [PubMed]

Chung, H.W.; Lee, J.Y.; Moon, H.-S.; Hur, S.E.; Park, M.H.; Wen, Y.; Polan, M.L. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. *Fertil. Steril.* 2002, 78, 787–795. [CrossRef]

Collette, T.; Bellehumeur, C.; Rats, R.; Meaux, R.; Mailloux, J.; Villeneuve, M.; Akoum, A. Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. *Hum. Reprod.* 2004, 19, 1257–1264. [CrossRef]

Matsuzaki, S.; Botchorishvili, R.; Pouly, J.L.; Canis, M. Targeting the Wnt/β-catenin pathway in endometriosis: A potentially effective approach for treatment and prevention. *Mol. Cell. Ther.* 2014, 2, 36. [CrossRef]

Cox, K.E.; Piva, M.; Sharpe-Timms, K.L. Differential regulation of matrix metalloproteinase-3 gene expression in endometriotic lesions compared with endometrium. *Biol. Reprod.* 2001, 65, 1297–1303. [CrossRef]

Ganguly, K.; Maity, P.; Reiter, R.J.; Swarnakar, S. Effect of melatonin on secreted and induced matrix metalloproteinase-9 and -2 activity during prevention of indomethacin-induced gastric ulcer. *J. Pineal Res.* 2005, 39, 307–315. [CrossRef]

Liu, D.; Shi, K.; Fu, M.; Chen, F. Melatonin indirectly decreases gastric cancer cell proliferation and invasion via effects on cancer-associated fibroblasts. *Life Sci.* 2021, 277, 119497. [CrossRef]

Mao, L.; Yuan, L.; Slakey, L.M.; Jones, F.E.; E. Burow, M.; Hill, S.M. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. *Breast Cancer Res. Ther.* 2010, 12, R107. [CrossRef]

Djordjevic, B.; Cvetkovic, T.; Stoimenov, T.J.; Despotovic, M.; Zivanovic, S.; Basic, J.; Veljkovic, A.; Kocic, G.; Pavlovic, D.; et al. Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes. *Eur. J. Pharmacol.* 2018, 833, 290–297. [CrossRef] [PubMed]

Akbar, M.A.; Movassaghpour, A.A.; Ghanbari, H.; Kheirandish, M.; Maroufi, N.F.; Rahbarghazi, R.; Nouri, M.; Samadi, N. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells. *Sci. Rep.* 2017, 7, 17062. [CrossRef]

Jardim-Persassi, B.V.; Lourenço, M.R.; Doho, G.M.; Grígolo, I.H.; Gelaleti, G.B.; Ferreirac, L.C.; Borin, T.F.; Moschetta, M.G.; Zuccari, D.A.P.D.C. Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines. *Anti-Cancer Agents Med. Chem.* 2016, 16, 347–358. [CrossRef] [PubMed]

Xie, M.; Hu, A.; Luo, Y.; Sun, W.; Hu, X.; Tang, S. Interleukin-4 and melatonin ameliorate high glucose and interleukin-1β stimulated inflammatory reaction in human retinal endothelial cells and retinal pigment epithelial cells. *Mol. Vis.* 2014, 20, 921–928. [PubMed]

Černyšiov, V.; Mauriccs, M.; Girkontaite, I. Melatonin inhibits granulocyte adherence to ICAM via MT3/QR2 and MT2 receptors. *Int. Immunol.* 2015, 27, 599–608. [CrossRef]

Matsuzaki, S.; Darcha, C. Epithelial to mesenchymal transition-like and mesenchymal to epithelial transition-like processes might be involved in the pathogenesis of pelvic endometriosis. *Hum. Reprod.* 2012, 27, 712–721. [CrossRef]

Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-Mesenchymal Transitions in Development and Disease. *Cell* 2009, 139, 871–890. [CrossRef]

Heerboth, S.; Housman, G.; Leary, M.; Longacre, M.; Byler, S.; Lapinska, K.; Willbanks, A.; Sarkar, S. EMT and tumor metastasis. *Clin. Transl. Med.* 2015, 4, 6. Available online: http://www.clintransmed.com/%5E%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed13&NEWS=N&AN=2015793182 (accessed on 26 September 2022). [CrossRef]

Min, C.; Eddy, S.F.; Sherr, D.H.; Sonenshein, G.E. NF-kB and epithelial to mesenchymal transition of cancer. *J. Cell. Biochem.* 2008, 104, 733–744. [CrossRef]
141. Lamouille, S.; Xu, J.; Derynick, R. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [CrossRef]
142. Li, Y.; Ma, J.; Qian, X.; Wu, Q.; Xia, J.; Miele, L.H.; Sarkar, F.H.; Wang, Z. Regulation of EMT by Notch signaling pathway in tumor progression. Curr. Cancer Drug Targets 2013, 13, 957–962. [CrossRef] [PubMed]
143. De Francesco, E.M.; Maggiolini, M.; Musti, A.M. Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT. Int. J. Mol. Sci. 2018, 19, 2011. [CrossRef]
144. Wu, S.-M.; Lin, W.-Y.; Shen, C.-C.; Pan, H.-C.; Bin, W.K.; Chen, Y.-C.; Jan, Y.-J.; Lai, D.-W.; Tang, S.-C.; Tien, H.-R.; et al. Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain-mediated C/EBPβ and NFκB B cleavage. J. Pineal Res. 2015, 60, 142–154. [CrossRef] [PubMed]
145. Wang, X.; Wang, B.; Xie, J.; Hou, D.; Zhang, H.; Huang. H. Melatonin inhibits epithelial-to-mesenchymal transition in gastric cancer cells via attenuation of IL-18/NF-κB/MMP2/MMP9 signaling. Int. J. Mol. Med. 2018, 42, 2221–2228. [CrossRef] [PubMed]
146. Ndo, N.G.; Colombo, J.; Lopes, J.R.; Gelaleti, G.B.; Moschetta, M.G.; Sonehara, N.M.; Hellmen, E.; Cde, F.Z.; Oliani, S.M.; Zuccari, D.A. Effect of Melatonin in Epithelial Mesenchymal Transition Markers and Invasive Properties of Breast Cancer Stem Cells of Canine and Human Cell Lines. PLoS ONE 2016, 11, e0150407. [CrossRef] [PubMed]
147. Mao, L.; Summers, W.; Xiang, S.; Yuan, L.; Dauchy, E.M.; Hanifin, J.P.; et al. Circadian Gating of Epithelial-to-Mesenchymal Transition in Breast Cancer Cells Via Melatonin-Regulation of GSK3β. Mol. Endocrinol. 2012, 26, 1808–1820. [CrossRef]
148. Agic, A.; Xu, H.; Finas, D.; Banz, C.; Diedrich, K.; Hornung, D. Is Endometriosis Associated with Systemic Subclinical Inflammation? Reprod. Updat. 2017, 24, 4087–4090. [CrossRef] [PubMed]
149. Lessey, B.A.; Lebovic, D.I.; Taylor, R.N. Eutopic Endometrium in Women with Endometriosis: Ground Zero for the Study of Advanced Endometriosis. Fertil. Steril. 2011, 96, 1021–1028.e1. [CrossRef]
150. Agic, A.; Xu, H.; Finas, D.; Banz, C.; Diedrich, K.; Hornung, D. Is Endometriosis Associated with Systemic Subclinical Inflammation? Gynecol. Obstet. Investig. 2006, 62, 139–147. [CrossRef] [PubMed]
151. Vallé-Juanico, J.; Houshdaran, S.; Giudice, L.C. The endometrial immune environment of women with endometriosis. Hum. Reprod. Updat. 2019, 25, 565–592. [CrossRef] [PubMed]
Mihalyi, A.; Gevaert, O.; Kyama, C.M.; Simsa, P.; Pochet, N.; De Smet, F.; De Moor, B.; Meuleman, C.; Billen, J.; Blancaert, N.; et al. Non-invasive diagnosis of endometriosis based on combination of six plasma biomarkers. *Hum. Reprod.* 2009, 25, 654–664. [CrossRef] [PubMed]

Vodolazkaia, A.; El-Aalam, Y.; Popovic, D.; Mihalyi, A.; Bossuyt, X.; Kyama, C.M.; Fassbender, A.; Bokor, A.; Schols, D.; Huskens, D.; et al. Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. *Hum. Reprod.* 2012, 27, 2698–2711. Available online: http://linker2.worldcat.org/?rft_id=129954&genre=&isbn=0268-1161&linkclass=a%3B%3Bkyama+c.%3Bfassbender%3Bbokor%3Bmeule (accessed on 26 September 2022). [CrossRef]

Currier, N.L.; Sun, L.Z.-Y.; Miller, S.C. Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity. *J. Neuroimmunol.* 2000, 104, 101–108. [CrossRef]

Miller, S.C.; Pandi, P.S.R.; Esquifino, A.I.; Cardinali, D.P.; Maestroni, G.J.M. The role of melatonin in immuno-enhancement: Potential application in cancer. *Int. J. Exp. Pathol.* 2006, 87, 81–87. [CrossRef]

Martins, E., Jr.; Fernandes, L.; Bartol, I.; Cipolla-Neto, J.; Rosa, L.C. The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumour-bearing rats. *J. Neuroimmunol.* 1998, 82, 81–89. [CrossRef]

Cho, J.H.; Bhutani, S.; Kim, C.H.; Irwin, M.R. Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials. *Brain Behav. Immun.* 2021, 93, 245–253. [CrossRef]

Stratton, P.; Berkley, K. Chronic pelvic pain and endometriosis: Translational evidence of the relationship and implications. *Hum. Reprod. Update* 2010, 17, 327–346. [CrossRef]

Morotti, M.; Vincent, K.; Brawn, J.; Zondervan, K.T.; Becker, C.M. Peripheral changes in endometriosis-associated pain. *Hum. Reprod. Update* 2014, 20, 717–736. [CrossRef]

Noeker, W.A.; Renz, H. Neurotrophins in allergic diseases: From neuronal growth factors to intercellular signaling molecules. *J. Allergy Clin. Immunol.* 2006, 117, 583–589. [CrossRef]

Niijs, J.; Meeus, M.; Versijpt, J.; Moens, M.; Bos, I.; Knaepen, K.; Meeusen, R. Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: A new therapeutic target? *Expert Opin. Ther. Targets* 2014, 19, 565–576. [CrossRef] [PubMed]

Robertson, N.J.; Faulkner, S.; Fleiss, B.; Bainbridge, A.; Andorka, C.; Price, D.; Powell, E.; Lecky-Thompson, L.; Thei, L.; Chandrasekaran, M.; et al. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. *Brain* 2012, 136, 90–105. [CrossRef] [PubMed]

Babaee, A.; Eftekhar-Vaghefi, S.H.; Asadi-Shekaari, M.; Shahrokhi, N.; Soltani, S.D.; Malekpour-Afshar, R.; Basiri, M. Melatonin treatment reduces apoptosis and astrogliosis in rats with traumatic brain injury. *Iran. J. Basic Med. Sci.* 2015, 18, 867–872. [CrossRef] [PubMed]

Srinivasan, V.; Pandi-Perumal, S.R.; Maestroni, G.J.M.; Esquifino, A.I.; Hardeland, R.; Cardinali, D.P. Role of melatonin in neurodegenerative diseases. *Neurotox. Res.* 2005, 7, 293–318. [CrossRef] [PubMed]

Morris, R.W.; Lutsch, E.F. Daily Susceptibility Rhythm to Morphine Analgesia. *J. Pharm. Sci.* 1969, 58, 374–376. [CrossRef]

Yu, C.-X.; Zhu, C.-B.; Xu, S.-F.; Cao, X.-D.; Wu, G.-C. The analgesic effects of peripheral and central administration of melatonin in rats. *Eur. J. Pharmacol.* 2000, 403, 49–53. [CrossRef] [PubMed]

El-Shenawy, S.M.; Abdel-Salam, O.M.; Baioumy, A.R.; El-Batran, S.; Arbid, M.S. Studies on the anti-inflammatory and antinociceptive effects of melatonin in the rat. *Pharmacol. Res.* 2002, 46, 235–243. [CrossRef]

Lopez-Canul, M.; Palazzo, E.; Dominguez-Lopez, S.; Luongo, L.; Lacoste, B.; Comai, S.; Angeloni, D.; Fraschini, F.; Boccella, S.; Spadoni, G.; et al. Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. *Pain* 2015, 156, 305–317. [CrossRef] [PubMed]

Masruba, M.R.; Vieira, D.S.D.S.; Minett, T.S.C.; Cipolla-Neto, J.; Zukermin, E.; Vilanova, L.C.P.; Peres, M.F.P. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. *J. Headache Pain* 2008, 9, 221–224. [CrossRef]

Leone, M.; D’Arinco, D.; Moschiano, F.; Fraschini, F.; Bussone, G. Melatonin Versus Placebo in the Prophylaxis of Cluster Headache: A double-blind pilot study with parallel groups. *Cephalalgia* 1996, 16, 494–496. [CrossRef] [PubMed]

Miano, S.; Parisi, P.; Pelliccia, A.; Luchetti, A.; Paolino, M.C.; Villa, M.P. Melatonin to prevent migraine or tension-type headache in children. *Neuroi. Sci.* 2008, 29, 285–287. [CrossRef] [PubMed]

Kurganova, Y.M.; Danilov, A. A role of melatonin in the treatment of low back pain. *Zhurnal Nevrol. Psikhiatrii Im. SS Korsakova* 2015, 115, 30–35. [CrossRef] [PubMed]

Hussain, S.A.-R.; Alkalhaila, I.; Jasim, N.A.; Gorial, F.I. Adjuvant use of melatonin for treatment of fibromyalgia. *J. Pineal Res.* 2010, 50, 267–271. [CrossRef] [PubMed]

Alghamdi, B.S. The neuroprotective role of melatonin in neurological disorders. *J. Neurosci. Res.* 2018, 96, 1136–1149. [CrossRef] [PubMed]

Karamitri, A.; Jockers, R. Melatonin in type 2 diabetes mellitus and obesity. *Nat. Rev. Endocrinol.* 2015, 11, 105–125. [CrossRef] [PubMed]

Wu, H.; Liu, J.; Yin, Y.; Zhang, D.; Xia, P.; Zhu, G. Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Anticancerogenic Action. *BioMed Res. Int.* 2019, 2019, 9740568. [CrossRef] [PubMed]

Alston, M.; Cain, S.W.; Rajaratnam, S.M.W. Advances of Melatonin-Based Therapies in the Treatment of Disturbed Sleep and Mood. *Sleep-Wake Neurobiol. Pharmacol.* 2015, 253, 305–319. [CrossRef] [PubMed]

Eryilmaz, O.G.; Devran, A.; Sarıkaya, E.; Aksakal, F.N.; Mollamahmutoğlu, L.; Ciec, N. Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems. *J. Assist. Reprod. Genet.* 2011, 28, 815–820. [CrossRef] [PubMed]
193. Batoğlu, A.S.; Şahin, U.; Gürlek, B.; Oztürk, N.; Unsal, E. The efficacy of melatonin administration on oocyte quality. *Gynecol. Endocrinol.* 2011, 28, 91–93. [CrossRef]

194. Fernando, S.; Wallace, E.M.; Vollenhoven, B.; Lolatgis, N.; Hope, N.; Wong, M.; Lawrence, M.; Lawrence, A.; Russell, C.; Leong, K.; et al. Melatonin in Assisted Reproductive Technology: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial. *Front. Endocrinol.* 2018, 9, 545. [CrossRef]

195. Takasaki, A.; Nakamura, Y.; Tamura, H.; Shimamura, K.; Morioka, H. Melatonin as a new drug for improving oocyte quality. *Reprod. Med. Biol.* 2003, 2, 139–144. [CrossRef] [PubMed]

196. Espino, J.; Macedo, M.; Lozano, G.; Ortiz, A.; Rodriguez, C.; Rodriguez, A.B.; Bejarano, I. Impact of Melatonin Supplementation in Women with Unexplained Infertility Undergoing Fertility Treatment. *Antioxidants* 2019, 8, 338. [CrossRef] [PubMed]

197. Jahromi, B.N.; Sadeghi, S.; Alipour, S.; Parsanezhad, M.E.; Alamdarloo, S.M. Effect of melatonin on the outcome of assisted reproductive technique cycles in women with diminished ovarian reserve: A double-blinded randomized clinical trial. *Eur. Rev. Med. Pharmacol. Sci.* 2018, 22, 73–78. [CrossRef]

198. Hobson, S.; Gurusinghe, S.; Lim, R.; Alers, N.O.; Miller, S.L.; Kingdom, J.C.; Wallace, E.M. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. *J. Pineal Res.* 2018, 65, e12508. [CrossRef]

199. Parandavar, N.; Abdali, K.; Keshtgar, S.; Esmaghaireishi, M.; Amooee, S. The Effect of Melatonin on Climacteric Symptoms in Menopausal Women; A Double-Blind, Randomized Controlled, Clinical Trial. *Iran. J. Public Health* 2011, 39, 91–93. [CrossRef]

200. Miller, S.L.; Yawno, T.; Alers, N.O.; Miller, S.L.; Kingdom, J.C.; Wallace, E.M. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. *J. Pineal Res.* 2018, 65, e12508. [CrossRef]

201. Hobson, S.; Gurusinghe, S.; Lim, R.; Alers, N.O.; Miller, S.L.; Kingdom, J.C.; Wallace, E.M. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. *J. Pineal Res.* 2018, 65, e12508. [CrossRef]

202. Parandavar, N.; Abdali, K.; Keshtgar, S.; Esmaghaireishi, M.; Amooee, S. The Effect of Melatonin on Climacteric Symptoms in Menopausal Women; A Double-Blind, Randomized Controlled, Clinical Trial. *Iran. J. Public Health* 2011, 39, 91–93. [CrossRef]

203. Hobson, S.; Gurusinghe, S.; Lim, R.; Alers, N.O.; Miller, S.L.; Kingdom, J.C.; Wallace, E.M. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. *J. Pineal Res.* 2018, 65, e12508. [CrossRef]

204. Nishihara, T.; Hashimoto, S.; Ito, K.; Nakaoka, Y.; Matsumoto, K.; Hosoi, Y.; Morimoto, Y. Oral melatonin supplementation improves oocyte and embryo quality in women undergoing in vitro fertilization-embryo transfer. *Gynecol. Endocrinol.* 2014, 30, 359–362. [CrossRef]

205. Miller, S.L.; Yawno, T.; Alers, N.O.; Castillo-Melendez, M.; Supramaniam, V.G.; Vanzyl, N.; Sabaretnam, T.; Loose, J.M.; Drummond, G.R.; Walker, D.W.; et al. Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction. *J. Pineal Res.* 2014, 56, 283–294. [CrossRef]

206. Espino, J.; Macedo, M.; Lozano, G.; Ortiz, A.; Rodriguez, C.; Rodriguez, A.B.; Bejarano, I. Impact of Melatonin Supplementation in Women with Unexplained Infertility Undergoing Fertility Treatment. *Antioxidants* 2019, 8, 338. [CrossRef] [PubMed]

207. Jahromi, B.N.; Sadeghi, S.; Alipour, S.; Parsanezhad, M.E.; Alamdarloo, S.M. Effect of melatonin on the outcome of assisted reproductive technique cycles in women with diminished ovarian reserve: A double-blinded randomized clinical trial. *Iran. J. Med. Sci.* 2017, 42, 73–78.

208. Parandavar, N.; Hojat, M.; Abdali, K.; Keshtgar, S.; Esmaghaireishi, M.; Yeganeh, B.S. The effect of melatonin on the lipid levels in menopausal women: A double-blind, controlled, clinical trial. *J. Educ. Health Promot.* 2018, 7, 144. [CrossRef]